#3DStartup: Carcinotech 3D Prints Tumors for Better Cancer Research

Cancer is one of the leading causes of death worldwide, estimated to account for nearly one in six deaths in 2020 alone. It is for that reason that research into treatment is such a large industry. However, advancements can be slow, not allowing current patients to take advantage of new innovations. But one startup may have a solution. Carcinotech uses 3D bioprinting to create living tumors that can be used for personalized treatment for each patient. We spoke with the CEO and founder, Ishani Malhotra, to learn more about the company, its technology and where it sees the role of 3D printing in healthcare.

3DN: Could you introduce yourself and your connection to 3D printing?

My name is Ishani Malhotra, I am the Chief Executive Officer and founder of Carcinotech. I have ten years of experience in oncology and stem cell research with degrees from the University of Edinburgh and a Certificate of Achievement from Harvard Medical School. Prior to launching Carcinotech, I also worked at Censo Biotechnologies, HCG Oncology hospitals, The Institute of Cytology and Preventative Oncology and Stempeutics. I was listed as a Director of the Year Regional finalist at the Institute of Directors Scotland 2021 awards and have won several awards at national and international platforms. I was recently recognized as one of 35 Rising Stars by Scottish Business Insider under 35, won the AccelerateHer 2022 Awards for Science and MedTech and won the Female Entrepreneur of the Year award at The Scottish SME Business Awards 2022.

Ishani Malhotra, the CEO of Carcinotech, along with her team

Carcinotech meanwhile is a MedTech company with expertise in manufacturing 3D-printed living tumors using patient-derived biopsies, primary cells, immune cells, and cancer stem cells. Carcinotech’s advanced models provide a platform for rapid, ethical, and accurate drug screening, pre-clinical and personalized medicine testing. As of now, I have established significant international partnerships to advance Carcinotech’s vision of providing personalized drug testing platforms to help those suffering from cancer. I have also worked with organizations across industry and academia including Cellink (provider of 3D bioprinters and medical devices) and Cancer Research UK to advance the validation of the company’s technology.